Europe continues to accelerate to finance its still scarce technological champions. The European Investment Bank, the Eurogroup and institutional investors from various member countries have joined forces to open a new chapter in the European Tech Champions Initiative (ETCI), a program to articulate capital that reaches the venture investment vehicles of the Twenty-seven to finance start-ups ("start-ups)and scalable (scale-ups) with more potential on the continent. The EIB has announced a second installment of the initiative, with the aim of attracting 15 billion euros to fuel European innovation.

The European Commission is looking for ways to spur European capital to foster its start-up ecosystem. The European Commissioner for Startups, Innovation and Research, Ekaterina Zaharieva, acknowledges a series of obstacles that still hinder the development of innovative sectors in the Twenty-seven. Among the most serious, she has pointed out the regulatory and financial fragmentation of the Union. She has also regretted the lack of venture capital to finance the large rounds and market exits with which many startups culminate their growth. Even more so with the advancement of the startup profile: in the last decade, the startup landscape was eminently digital and service-oriented. Now, with a focus on deep technology, much more capital-intensive, the problem becomes even more serious, according to sources in the technology sector consulted. A technology that, in its development phase, is more than present in the EU: "We have everything we need to lead," Zaharieva states.

New strategy. The Catalan Institute of Finance (ICF) will increase the resources allocated to venture capital investments to €645 million to support "transformative business projects that contribute to Catalonia's economic leadership."

AltamarCAM Partners, a global investment firm specializing in private markets, and Asabys Partners, a Catalan private equity firm specializing in healthcare, have reached an agreement to integrate Altamar's healthcare and life sciences team, previously part of its subsidiary Aliath Bioventures, into Asabys, and Ligafescie into the Alta fund.